Jean-François Deleuze,Ph.D (CNRGH/CEPH) is, since October 2012, both the director of the Centre National de Recherche en Génomique Humaine (CNRGH) and the scientific director of the Centre d’ Etudes du Polymorphisme Humain (CEPH). JF Deleuze began his career in the pharmaceutical industry working for Rhône Poulenc Rorer and then Aventis and finally Sanofi where he established and headed the worldwide Human Genetics center of the company (40 people) for about 10 years. JF Deleuze has coordinated numerous international translational research collaborative projects (identification of biomarkers and therapeutic targets) in the field of the genetics of multifactorial diseases (schizophrenia, bipolar disorder, Alzheimer's ...) and cancer, involving academic groups but also biotechnology companies. JF Deleuze was one of the initiators/pioneers of the introduction of personalized medicine approaches in the pharmaceutical industry. In his last 2 years at Sanofi, JF Deleuze built an efficient and state of the art stem cell platform, that has delivered world-class translational tools and disease models. Beside his actual leadership positions at CNRGH and CEPH, JF Deleuze is executive board member of France Génomique and heads the laboratory of Excellence (Labex) GenMed dedicated to the development of personalized medicine. Recently, JF Deleuze played a pivotal role in the development of the French Genomic Medicine Plan (FMG2025) and he will lead the Center of Reference, Innovation and Expertise (CREFIX) of the plan. JF Deleuze is the author of 160 scientific publications and 15 patents in the field of genetics/genomic medicine.